Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care ...

Therefore, knowing a company's potential revenue growth is crucial. For Merck, the consensus sales estimate for the current quarter of $15.52 billion indicates a year-over-year change of +6.1%.

Merck & Co’s Keytruda cancer immunotherapy is set to become the world’s top-selling drug by annual revenue in 2023, smashing sales records set by AbbVie’s ageing inflammatory disease drug ...

BMO Capital analyst Evan Seigerman has maintained their neutral stance on MRK stock, giving a Hold rating on January 10.Stay Ahead of the ...

Shares of this pharmaceutical company have returned +1.2% over the past month versus the Zacks S&P 500 composite's -1.6% change. The Zacks Large Cap Pharmaceuticals industry, to which Merck ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...

2025 China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million, ahead of potential U.S. legislation that would restrict ...